Document is current
Any future updates will be listed below
-
Authors
Margolese, Howard C. http://orcid.org/0000-0002-3912-0566
Boucher, Matthieu
Therrien, Francois
Clerzius, Guerline
-
Funding
Funding for this research was provided by:
Lundbeck Canada Inc. (Lundbeck Canada Inc.)
Otsuka Canada Pharmaceutical Inc. (Otsuka Canada Pharmaceutical Inc.)
- License Information
-
More Information
Article History
Received: 12 May 2022
Accepted: 16 November 2022
First Online: 8 December 2022
Declarations
:
: All patients signed an informed consent form before any study related procedures were performed for the ReLiAM study. Central Ethics approval was obtained from IRB Services, Aurora, Ontario, Canada. In addition, approval from local institutional ethics boards (University of Windsor, McGill University Health Centre, Institut Universitaire en Sante Mentale de Quebec, Capital Health, Ottawa Health Science Network, Royal Ottawa Health Care Group, University of Calgary, Western University, Queen’s University, Douglas Mental Health Institute, University of British Columbia) was obtained as required.
: Not applicable.
: HCM has received research/grant support from the Montreal General Hospital Foundation, Aifred health, Lundbeck, Otsuka and SyneuRx; and has received honoraria as a paid speaker and/or consultant for AbbVie, HLS Therapeutics, Janssen, Lundbeck, Otsuka, Sunovion and Teva. MB is a full-time employee of Otsuka Canada Pharmaceutical Inc. and affiliate member of the Department of Pharmacology & Therapeutics, Faculty of Medicine and Health Sciences at McGill University, Montreal, Canada.FT is a full-time employee of Otsuka Canada Pharmaceutical Inc.GC was a full-time employee of Lundbeck Canada Inc at the time of this analysis.
